Peter Nielsen co-founded Bio-Path Holdings, a public biotechnology company developing targeted oncology therapies, and currently serves as Bio-Path’s president, chief executive officer, chief financial officer and chairman of the board of directors. At the time of Bio-Path’s establishment in 2007, Mr. Nielsen licensed technology and targets from the University of Texas M.D. Anderson Cancer Center and coordinated pre-clinical development, optimization and manufacturing of Bio-Path’s lead product, BP1001. Over the next ten years, Mr. Nielsen led the clinical advancement of BP1001 into Phase 2 studies, the introduction of additional pipeline candidates, and the company’s public market debut. Prior to co-founding Bio-Path, Mr. Nielsen has worked with several other companies, leading turnarounds and developing and executing on strategies for growth. He currently serves as a director of Bio-Path and of Synthecon, Inc., a company developing 3D cell culture technology. Before entering the biotechnology sector, Mr. Nielsen was a lieutenant in the U.S. Naval Nuclear Power program where he was director of the physics department, and was employed at Ford Motor Company in product development. Mr. Nielsen has a broad background in senior management and has significant negotiating experience. He has earned degrees in engineering, mathematics and an MBA in finance from the University of California at Berkeley.
Dr. Ana Tari Ashizawa is a scientific co-founder of Bio-Path Holdings and serves as director of research for the company. Dr. Tari Ashizawa is a leading expert in liposomes, and was instrumental in the development of Bio-Path’s neutral lipid delivery technology. She was previously an associate professor at the University of Texas M.D. Anderson Cancer Center and the University of Florida, Gainesville. Dr. Tari Ashizawa holds a doctorate in biochemistry from the University of Tennessee, and a Master of Business Administration from the University of Florida.
Anthony Price serves as the director of finance and accounting. He joined Bio-Path in May 2014 with over 10 years of experience in the healthcare field. From October 2006 through April 2014, he held positions in finance at Lexicon Pharmaceuticals, Inc., most recently as associate director of finance and accounting. From 1993 to 2006, Mr. Price served in a variety of financial and accounting management positions for Building Materials Holding Corporation. Mr. Price holds a Bachelor of Science in business administration – finance from California State University, Fresno and a Master of Business Administration from Colorado State University.
Michael Hickey has broad expertise in oncology and rare disease clinical drug development, especially focused on challenging indications such as head-and-neck cancer, colorectal cancer, breast cancer with BRCA mutations as well as program development for chemotherapy induced myelosuppression, hemophilia, and Battens Disease. At Bio-Path Holdings, Mr. Hickey will be responsible for development, implementation and oversight of the company’s ongoing and planned trials. Mr. Hickey has held positions of increasing responsibility at Amgen, BioMarin, PPD and G1 Therapeutics, where he managed domestic and global drug development programs from their earliest clinical stages through regulatory submission. His experience in clinical development includes the regulatory approval of Brineura®, Kepivance®, and post-marketing development of Neupogen®/Neulasta®. In addition to his career activities, Mr. Hickey is a member of the Project Management Institute (PMI) and the Drug Information Association (DIA) the foremost professional organization in this field, responsible for setting standards for professional competence and promoting excellence in project management and drug development. Mr. Hickey earned his Bachelor of Science from the University of Southern California and an MBA from California State University at San Marcos.
Michael Roberts is the company’s director of manufacturing planning and engineering. He joined Bio-Path in September of 2014. Michael brings over 17 years of cGMP lipid manufacturing and liposomal formulation experience. He has worked with Bio-Path’s leadership team on development projects for all of Bio-Path’s pipeline drug products. Michael received his Bachelor of Science in chemical engineering from the University of Alabama in Huntsville.